Last week I was in Chicago, where the Society of Gynecologic Oncology (SGO) Program Committee was hard at work organizing a bounty of exceptional abstracts for the 2014 Annual Meeting on Women’s Cancer®. The committee received an astounding 909 abstracts (an increase of 198 over last year) and had the joy, and hardship, of selecting the best cross section of submissions. Because our members are conducting so much high quality research, it is imperative for SGO to offer prestigious vehicles in which to present it.
For this reason, I am especially pleased to share with you the results of our new agreement with Elsevier, publisher of Gynecologic Oncology. Although I am a deputy editor, I can say quite objectively as SGO President that this agreement elevates the status of SGO’s official journal.
Beginning in January 2014, Gynecologic Oncology will move from Elsevier’s Life Sciences portfolio to its Oncology portfolio. The journal will be managed and promoted alongside The Lancet and Lancet Oncology, European Journal of Cancer and other specialist cancer journals. We will enjoy physical promotion of the journal at relevant oncology meetings, cross promotion of special content and opportunities for discounted rates to select journals for SGO members. The journal will continue to reside online at ScienceDirect but also join the HealthAdvance platform that is customized for Elsevier’s society partners.
Under the leadership of Editor-in-Chief Beth Y. Karlan, MD, Gynecologic Oncology’s impact factor continues to increase, from 3.888 in 2011 to 3.929 in 2012. Recall that in 2008 the impact factor was 2.919. In addition, publication turnaround continues to shrink. Submission to first decision is now four weeks. Submission to final decision is 5.9 weeks, and submission to online publication is 14.3 weeks. The latter figure was 23.6 weeks in 2005.
The journal will publish special themed issues once a year. In 2014, a special issue on obesity will be published in April, featuring abstracts presented at the 2014 Annual Meeting. Abstracts will be published online and in print simultaneously. In addition, we have already begun to promote the lead article and editorial of each issue on the SGO home page, and the journal is providing open access to them.
Dr. Karlan said this arrangement is good for the Journal and Elsevier as well as SGO, its members, and the greater gynecologic oncology community. “I’m extremely pleased with the Journal’s progress, new initiatives and partnerships,” she said. “These moves by Elsevier demonstrate their support of Gynecologic Oncology and further confirm that we are moving in the right direction.”
I commend Dr. Karlan and fellow deputy editors Robert E. Bristow, MD; David E. Cohn, MD; Laurel W. Rice, MD; Stephen C. Rubin, MD; and Anil K. Sood, MD; the entire Editorial Board; and the staff at Elsevier.
Clearly, Gynecologic Oncology is taking its rightful place among the most prestigious scientific journals in the oncology space. By submitting your best research to the official SGO journal, you will enjoy recognition not only among your peers in gynecologic oncology, but also within a significantly broader medical community. You also will contribute to the further elevation of gynecologic oncology as an indispensable profession in the treatment of women’s cancers.
I thoroughly enjoyed seeing many of my fellow SGO members at the National Race to End Women’s Cancer yesterday. Looking ahead to the 2014 Annual Meeting on Women’s Cancer, March 22-25, it’s not too early to start making plans. Registration and housing open Nov. 11. Details about the meeting will be posted at www.sgo.org/annualmeeting as they become available. I’m sure you will like what you see!
As always, I welcome your feedback. Please write to me at email@example.com.
Barbara A. Goff, MD